

Adaptive Monitoring: Optimal wait-time to control false discoveries

Jonathan J Chipman, PhD

Population Health Sciences, Division of Biostatistics
University of Utah
Huntsman Cancer Institute

March 23, 2020

Overview

Co-authors Jeffrey D Blume, PhD and Robert A Greevy, Jr., PhD

AM SGPV Adaptive monitoring on Second Generation p-Value
(Chipman 2019)

Burn-in To ensure $\alpha < 0.05$ with unlimited sample size

Prematurely Ending Clinical Trial(s)

Towards a Revolution in COPD Health (TORCH) (Calverley 2007)

Primary Aim: Establish whether beta-agonist (salmeterol plus fluticasone propionate) has survival benefit in participants with chronic obstructive pulmonary disease

2007 6112 participants

- ▶ HR 0.825 (95% CI: 0.681-1.002, p-adjusted=0.052)
- ▶ Awkward Conclusion: primary outcome did not reach statistical significance, yet 'significant benefits in all other outcomes.'

Prematurely Ending Clinical Trial(s)

Towards a Revolution in COPD Health (TORCH) (Calverley 2007)

Primary Aim: Establish whether beta-agonist (salmeterol plus fluticasone propionate) has survival benefit in participants with chronic obstructive pulmonary disease

2007 6112 participants

- ▶ HR 0.825 (95% CI: 0.681-1.000, p-adjusted=0.05)
- ▶ Awkward Conclusion: primary outcome did not reach statistical significance, yet 'significant benefits in all other outcomes.'

Prematurely Ending Clinical Trial(s)


Towards a Revolution in COPD Health (TORCH) (Calverley 2007)

Primary Aim: Establish whether beta-agonist (salmeterol plus fluticasone propionate) has survival benefit in participants with chronic obstructive pulmonary disease


2007 6112 participants

- ▶ HR 0.825 (95% CI: 0.681-0.998, p-adjusted=0.0498)
- ▶ Awkward Conclusion: primary outcome did not reach statistical significance, yet 'significant benefits in all other outcomes.'


Envisioning treatment effects




Envisioning treatment effects




Region of Practically Equivalent Effects (ROPE) (Kruschke 2011)



Region of Practically Equivalent Effects (ROPE) (Kruschke 2011)



Region of Meaningful Effects (ROME)




A forest plot illustrating hazard ratios. The x-axis is labeled 'Hazard Ratio' and has tick marks at 0.925, 0.975, 1.025, and 1.075. A vertical dashed line is drawn at 1.0. The plot shows seven horizontal lines representing hazard ratios. The top six lines are labeled 'Observed' and 'Hypothetical' on the right side. The bottom line is labeled 'Hypothetical'. The lines are colored blue and are positioned at various points relative to the 1.0 line.

Category	Hazard Ratio (approx.)
Observed	0.95
Hypothetical	0.96
Hypothetical	0.97
Hypothetical	0.98
Hypothetical	0.99
Hypothetical	1.01
Hypothetical	1.02

Second Generation p-value (SGPV; Blume et al. 2018, 2019)


What proportion of interval overlaps with Δ_H ?



Interpretation of p_H

- ▶ $p_H = 0$: Evidence to rule out hypothesis effects
- ▶ $p_H = 1$: Evidence supporting hypothesis effects
- ▶ $0 < p_H < 1$: Inconclusive, need more data

TORCH with ROPE and ROME



Observed

 $0 < p_{\text{ROPE}} < 1 ; 0 < p_{\text{ROME}} < 1$

Hypothetical

 $0 < p_{\text{ROPE}} < 1 ; 0 < p_{\text{ROME}} < 1$

Hypothetical

 $0 < p_{\text{ROPE}} < 1 ; 0 < p_{\text{ROME}} < 1$

Hypothetical

 $0 < p_{\text{ROPE}} < 1 ; p_{\text{ROME}} = 0$

Hypothetical

 $p_{\text{ROPE}} = 0 ; 0 < p_{\text{ROME}} < 1$

Hypothetical

 $p_{\text{ROPE}} = 0 ; 0 < p_{\text{ROME}} < 1$

Hypothetical

 $p_{\text{ROPE}} = 0 ; p_{\text{ROME}} = 0$

Adaptive Monitoring with SGPV

Wait Interval width stabilizes

Monitor Interval and SGPV at desired looks

Alert $p_{ROPE} = 0.0$: Ruled out ROPE effects

$p_{ROME} = 0.0$: Ruled out ROME effects

Affirm Stop if same conclusion k participants later
End of resources

Report Only the final interval when stopping

Adaptive Monitoring with SGPV

- Wait** Interval width stabilizes
- Monitor** Interval and SGPV at desired looks
 - Alert** $p_{ROPE} = 0.0$: Ruled out ROPE effects
 $p_{ROME} = 0.0$: Ruled out ROME effects
 - Affirm** Stop if same conclusion k participants later
End of resources
 - Report** Only the final interval when stopping

Adaptive Monitoring with SGPV

- Wait** Interval width stabilizes
- Monitor** Interval and SGPV at desired looks
 - Alert** $p_{ROPE} = 0.0$: Ruled out ROPE effects
 $p_{ROME} = 0.0$: Ruled out ROME effects
 - Affirm** Stop if same conclusion k participants later
End of resources
 - Report** Only the final interval when stopping

Adaptive Monitoring with SGPV

- Wait** Interval width stabilizes
- Monitor** Interval and SGPV at desired looks
 - Alert** $p_{ROPE} = 0.0$: Ruled out ROPE effects
 $p_{ROME} = 0.0$: Ruled out ROME effects
 - Affirm** Stop if same conclusion k participants later
End of resources
 - Report** Only the final interval when stopping

Error probabilities

Error probabilities (such as Type I Error) depend on

- ▶ ROPE and ROME
- ▶ Wait time
- ▶ Affirmation steps (k)

Error probabilities

Error probabilities (such as Type I Error) depend on

- ▶ ROPE and ROME (set by science)
- ▶ Wait time
- ▶ Affirmation steps

Wait time with unlimited sample size

- ▶ Measured by inferential width


Controlling errors

Simulations with 40K replicates with varying wait times


Holding constant:

- ▶ Control $\sim N(0,1)$, Treated $\sim N(0,1)$
- ▶ ROME and ROPE regions (10 settings)
- ▶ $k = 0$

How long to wait before applying monitoring rules: A one-sided example




How long to wait before applying monitoring rules: A one-sided example




Wait until expected margin if error (1/2 width of CI) is 0.5

How long to wait before applying monitoring rules: A one-sided example



Wait until expected margin of error (1/2 width of CI) is 0.25


How long to wait before applying monitoring rules: A one-sided example



Wait until expected margin if error (1/2 width of CI) is 0.15


Type I Error

Type I Error ; P (Reject Point Null | Theta = 0)




Type I Error

Type I Error ; P (Reject Point Null | Theta = 0)




Type I Error

Type I Error ; P (Reject Point Null | Theta = 0)



Type I Error

Type I Error ; P (Reject Point Null | Theta = 0)



Conclusions

- 1 AM SGPV novel design to follow studies until ruling out practically null or meaningful effects
- 2 With immediate stopping ($k=0$) and unlimited sample size, Type I error can be controlled through the wait time.

Thank you and questions